New drug duo tested for tough-to-treat breast cancer
NCT ID NCT05963997
Summary
This study tested whether combining two drugs, samuraciclib and elacestrant, is safe and effective for people with advanced hormone-positive, HER2-negative breast cancer that has progressed on standard therapy. It involved 49 adult participants internationally. The trial first aimed to find a safe dose, then assessed if the combination could control cancer growth and shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 12 - Belfast City Hospital
Belfast, United Kingdom
-
Site 2 - Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Site 32 - Swedish Medical Center, Swedish Cancer Institute (SCI),Cherry Hill Campus
Seattle, Washington, 98122, United States
-
Site 35 - Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio, 44106, United States
-
Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University
Chicago, Illinois, 60611, United States
-
Site 4 - The Christie NHS Foundation Trust
Manchester, United Kingdom
-
Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology
San Antonio, Texas, 78229, United States
-
Site 42 - Dana-Farber Cancer Institute, EDDC
Boston, Massachusetts, 02215, United States
-
Site 60 - NEXT Oncology EU Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Spain
-
Site 61 - Institut Catala d'Oncologia (ICO), Hospital Duran i Reynals Location
L'Hospitalet de Llobregat, Spain
-
Site 62 - Universidad de Navarra, Clinica Universidad de Navarra (CUN)
Madrid, Spain
-
Site 63 - South Texas Accelerated Research Therapeutics, CIOCC, Hospital Madrid Norte-Sanchinarro
Madrid, Spain
-
Site 64 - Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona, Spain
-
Site 65 - Complexo Hospitalario Universitario A Coruña
A Coruña, Spain
-
Site 66 - Hospital Clinico San Carlos
Madrid, Spain
-
Site 67 - Universidad de Sevilla, Hospital Universitario Virgen Macarena
Seville, Spain
-
Site 68 -Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Site 69 - Universidad de Navarra - Clinica Universidad de Navarra (CUN)
Pamplona, Spain
-
Site 80 - Centre Jean Bernard, Clinique Victor Hugo
Le Mans, France
-
Site 81 - Bergonie unicancer, Nouvelle-Aquitaine, L'Institut Bergonie
Bordeaux, France
-
Site 82 - Institut de Cancerologie de Ouest (ICO)
Saint-Herblain, France
-
Site 83 - Institut Paoli Calmettes (IPC)
Marseille, France
-
Site 85 - Institut Curie
Paris, France
Conditions
Explore the condition pages connected to this study.